Triptolide reduces prostate size and androgen level on testosterone-induced benign prostatic hyperplasia in Sprague Dawley rats  

作　　者：WANG Yu-Rong XU Yuan JIANG Zhen-Zhou ZHANG Lu-Yong WANG Tao 

机构地区：[1]State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China [2]Center for Molecular Metabolism, School of Environmental and Biological Engineering, Nanjing University of Science andTechnology, Nanjing 210014, China [3]Jiangsu Key Laboratory of Drug Screening and Jiangsu Center for Pharmacodynamics Research and Evaluation, China Pharmaceutical University, Nanjing 210009, China [4]Jiangsu Key Laboratory of TCM Evaluation and Translational Research, China Pharmaceutical University, Nanjing 210009,China

出　　处：《Chinese Journal of Natural Medicines》2017年第5期341-346,共6页中国天然药物（英文版）

基　　金：supported by National Natural Science Foundation of China(Nos.81173651,81320108029,and 81303301);the 2011’ Program for Excellent Scientific and Technological Innovation Team of Jiangsu Higher Education,“the 111 Project(111-2-07)”

摘　　要：Benign prostatic hyperplasia(BPH) is an age-related disease of unknown etiology, characterized by prostatic enlargement coincident with distinct alterations in tissue histology. In the present study, we investigated whether triptolide can prevent testosterone-induced prostatic hyperplasia in rats. Castration was performed via the scrotal route after urethane aesthesia. BPH was induced in experimental groups by daily subcutaneous injections of testosterone propionate(TP) for two weeks. Triptolide was administered daily by oral gavage at a dose of 100 and 50 μg×kg^(-1) for 2 weeks, along with the TP injections. On day 14, the animals were humanely killed by cervical dislocation after aesthesia. Prostates were excised, weighed, and used for histological studies. Testosterone and dihydrotestosterone(DHT) levels in serum and prostate were measured. The results showed that triptolide significantly reduced the prostate weight, and the testosterone and DHT levels in both the serum and prostate. Histopathological examination also showed that triptolide treatment suppressed TP-induced prostatic hyperplasia. In conclusion, triptolide effectively inhibits the development of BPH induced by testosterone in a rat model.Benign prostatic hyperplasia （BPH） is an age-related disease of unknown etiology, characterized by prostatic enlargement coincident with distinct alterations in tissue histology. In the present study, we investigated whether triptolide can prevent testosterone-induced prostatic hyperplasia in rats. Castration was performed via the scrotal route after urethane aesthesia. BPH was induced in experimental groups by daily subcutaneous injections of testosterone propionate （TP） for two weeks. Triptolide was administered daily by oral gavage at a dose of 100 and 50 p.g.kg-1 for 2 weeks, along with the TP injections. On day 14, the animals were humanely killed by cervical dislocation after aesthesia. Prostates were excised, weighed, and used for histological studies. Testosterone and dihydrotestosterone （DHT） levels in serum and prostate were measured. The results showed that triptolide significantly reduced the prostate weight, and the testosterone and DHT levels in both the serum and prostate. Histopathological examination also showed that triptolide treatment suppressed TP-induced prostatic hyperplasia. In conclusion, triptolide effectively inhibits the development of BPH induced by testosterone in a rat model.

关 键 词：TRIPTOLIDE Benign prostatic hyperplasia ANDROGEN 

分 类 号：R965[医药卫生—药理学]